173 related articles for article (PubMed ID: 32107047)
1. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
Choi CH; Chung JY; Kang JH; Paik ES; Lee YY; Park W; Byeon SJ; Chung EJ; Kim BG; Hewitt SM; Bae DS
Gynecol Oncol; 2020 May; 157(2):437-443. PubMed ID: 32107047
[TBL] [Abstract][Full Text] [Related]
2. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
4. Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy.
Gaber G; El Achy S; Khedr GA; Parimi V; Helenowksi I; Donnelly ED; Strauss JB; Woloschak G; Wei JJ; Small W; Refaat T
Am J Clin Oncol; 2021 Feb; 44(2):58-67. PubMed ID: 33284239
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
Liao SY; Darcy KM; Randall LM; Tian C; Monk BJ; Burger RA; Fruehauf JP; Peters WA; Stock RJ; Stanbridge EJ
Gynecol Oncol; 2010 Mar; 116(3):452-8. PubMed ID: 19913895
[TBL] [Abstract][Full Text] [Related]
6. c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.
Refaat T; Donnelly ED; Sachdev S; Parimi V; El Achy S; Dalal P; Farouk M; Berg N; Helenowski I; Gross JP; Lurain J; Strauss JB; Woloschak G; Wei JJ; Small W
Am J Clin Oncol; 2017 Dec; 40(6):590-597. PubMed ID: 26083558
[TBL] [Abstract][Full Text] [Related]
7. MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.
Kang HB; Kim SH; Lee JH; Lee HC; Kang NK; Lee JH
Int J Clin Oncol; 2024 May; 29(5):620-628. PubMed ID: 38530569
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Nuclear Factor Kappa B Expression in Locally Advanced Cervical Cancer Patients Treated Definitively With Concurrent Chemoradiation.
Altoos B; Small C; Dalal P; Attieh D; El Achy S; Parimi V; Wei JJ; Helenowski I; Donnelly ED; Strauss J; Small W; Refaat T
Am J Clin Oncol; 2020 Jan; 43(1):47-51. PubMed ID: 31693509
[TBL] [Abstract][Full Text] [Related]
9. Excision repair cross-complementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy.
Liang ZL; Song EK; Ko YB; Lee NR; Yhim HY; Noh HT; Yun HJ; Suh KS; Jo DY; Kim S; Kim JS; Kim JM; Lee HJ
Histopathology; 2011 Sep; 59(3):564-7. PubMed ID: 22034895
[No Abstract] [Full Text] [Related]
10. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
11. Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry.
Jeong SY; Chung JY; Byeon SJ; Kim CJ; Lee YY; Kim TJ; Lee JW; Kim BG; Chae YL; Oh SY; Choi CH
Front Oncol; 2021; 11():665595. PubMed ID: 34350111
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy.
Rojas-Puentes L; Cardona AF; Carranza H; Vargas C; Jaramillo LF; Zea D; Cetina L; Wills B; Ruiz-Garcia E; Arrieta O
Cancer Med; 2016 Aug; 5(8):1989-99. PubMed ID: 27230280
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
14. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
15. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
[TBL] [Abstract][Full Text] [Related]
16. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
[TBL] [Abstract][Full Text] [Related]
17. Survivin protein as predictor of pathologic response in patients with locally advanced cervical cancer treated with chemoradiation followed by radical surgery.
Zannoni GF; Petrillo M; Vellone VG; Martinelli E; Chiarello G; Ferrandina G; Scambia G
Hum Pathol; 2014 Sep; 45(9):1872-8. PubMed ID: 24997647
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Rodrigo RS; Nathalie A; Elodie T; Gonzalo GA; Philippe T; Françoise D; Julien D; Angela C; Bérénice B; Jean-Yves B; Jean-Michel C; Jean B; Sylvie B; Axel le C
Eur J Cancer; 2011 Jun; 47(9):1319-27. PubMed ID: 21450455
[TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
